Health and Me

Tanya Dutt

India’s First Indigenous Dengue Vaccine Coming Soon; What To Expect?

DengiAll: India’s First Indigenous Dengue Vaccine Nears Completion, Set to Hit Markets by Next Year

Dengue fever has been a public health crisis for decades, especially in tropical and subtropical regions, and India has been one of the worst-hit countries in recent years. With rising cases and fatal outbreaks, the country has required a reliable and inexpensive vaccine to prevent the spread of the disease. That changed with the launch of <span>DengiAll</span>, India's indigenous tetravalent <span>dengue vaccine</span>. After all these years of research, trials, and international collaboration, the vaccine is now in the last stage of testing, and a breakthrough seems at hand.

Developed by the Indian Council of Medical Research (ICMR) in collaboration with Panacea Biotech, DengiAll will be a game-changer for India's battle against dengue. The vaccine is currently in Phase 3 clinical trials, which are being conducted at 19 sites in 18 states and union territories with more than 10,335 healthy volunteers enrolled so far. The trials have shown promising results, with earlier phases (1 and 2) being successful for the vaccine to combat dengue across various strains.

The significance of the vaccine is not just its possibility in dengue prevention but also that it's an indigenous development, carefully crafted to fulfill India's needs. Balram Bhargava, former Director General of ICMR, who has played a key role in India's fight against COVID-19, ensured that India's first indigenous tetravalent dengue vaccine will be in the market by mid-2026—a landmark moment for India's health sector.

Dengue fever, transmitted by the Aedes aegypti mosquito, is one of the most common vector-borne diseases in India, especially prevalent during the monsoon season between May and September. The disease is characterized by fever, severe headache, joint pains, and sudden drop in platelet levels. It can, in severe cases, progress to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), which will prove fatal without urgent medical treatment. The World Health Organization (WHO) indicates that the worldwide incidence of dengue has grown eight times greater than two decades ago, thus emerging as a public health issue of major concern.

DengiAll is a <span>tetravalent vaccine</span>, and it has the goal of protecting against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). This is a significant feature since dengue is a multi-serotype disease, and immunity to one serotype will not protect against others. In protecting against all four serotypes, the vaccine provides broad protection, which is extremely important in a country like India, where outbreaks are ever-present and in large part unpredictable.

The vaccine development is based on the TV003/TV005 strain, which was originally developed by the United States' National Institutes of Health (NIH). The strain was licensed to Panacea Biotech, a top Indian pharma company, and was adapted for domestic use. The company has achieved significant milestones in re-developing the vaccine to meet the specific needs of the Indian population, for whom it holds a process patent for development.

<h2>Highest Number of Cases Recorded In India</h2>

Approximately 188,401 cases were identified in 2017, with 325 deaths. Highest number of infections was reported from Tamil Nadu, followed by Kerala, Karnataka, then Punjab and West Bengal. In the 20th century, there was the significant rise in number of infections reported in 2003, 2010, 2012, and 2013, with an exponential increase beginning in 2015 onwards. During this time, repeated dengue outbreaks were reported in states of Andhra Pradesh, Goa, Delhi, Haryana, Karnataka, Gujarat, Kerala, Tamil Nadu, Punjab, and West Bengal. In 2017, dengue cases were to be the highest in India. 

India, in particular, has experienced frequent outbreaks in West Bengal, Uttar Pradesh, Rajasthan, Bihar, Delhi, Kerala, and Tamil Nadu. The outbreaks have claimed thousands of lives and loaded the healthcare system with a great burden. Over 5 million cases of dengue have been reported to date as of 2023, with the Indian contribution playing a significant role in the surge. Since DengiAll is presently in its final stages of trials, the vaccine is set to reduce significantly the incidence of dengue and its complications in the country.

<h2>Why Dengue Cases Are On A Steady Rise?</h2>

Although India has been battling with dengue for years now, the illness has also been on the rise globally. The WHO states that the number of dengue cases reported globally has grown over twice in the past few years, with a total of 10.6 million cases having been reported thus far in the year 2024 alone. The growth is driven by various factors:

<ul><li>Warm, humid temperatures offer ideal breeding grounds for mosquitoes.</li><li>Overcrowded cities with poor waste management infrastructure facilitate the disease transmission.</li><li>Increased international travel has led to dengue's expansion into non-endemic areas.</li></ul>

There is no cure for dengue known at the moment. It is treated with supportive care—hydration, management of fever, and close attention to platelet levels. If it is severe, hospitalization is required, and there are concerns regarding the burden this causes to the health system, especially in low-resource settings.

The presence of a dengue vaccine like DengiAll would be a welcome preventive. While a vaccine would not replace effective measures for mosquito control, it could be an extra tool in the public health arsenal, significantly reducing the number of severe cases and fatalities.

<h2>When Will Dengue Vaccine Hit the Market?</h2>

So far, DengiAll is in <span>Phase 3 trials</span>, and although it shows a great deal of promise, it should be kept in mind that the final approval phase could take time. If the ongoing trials continue to progress well, it is hoped that the vaccine would become available by mid-2026. This is a rough estimate, though, as it includes successful completion of the clinical trials and regulatory approvals.

<h2>Signs and Symptoms of Dengue Fever</h2>

Symptoms of dengue fever typically appear 4 to 10 days from the time of a bite from an infected mosquito and persist for 3 to 7 days. Asymptomatic cases are most common, but about 1 in 20 individuals will experience severe dengue when the initial symptoms start to resolve. Typical symptoms of dengue fever are:

<ul><li>High fever</li><li>Rash</li><li>Severe pain behind the eyes</li><li>Nausea and vomiting</li><li>Muscle, bone, and joint pain</li></ul>

If you notice any of these symptoms, it is imperative that you receive medical care immediately, particularly if the symptoms are increasing.

<h2>How Does Vaccine Affects Dengue Treatment?</h2>

The DengiAll vaccine, India’s pioneering tetravalent dengue vaccine developed by Panacea Biotec, targets all four dengue serotypes, offering a preventive approach that could revolutionize dengue management. Dr. Divya Gopal, Consultant - Internal Medicine, Sir HN Reliance Foundation Hospital, Mumbai says, "Currently in Phase 3 trials with over 10,000 participants, it may reach markets by mid-2026 if successful. Unlike existing treatments, which focus on symptom management due to the absence of specific antivirals, DengiAll aims to reduce infection rates and disease severity, potentially lowering hospitalization and mortality, particularly during monsoon seasons. By shifting focus to prevention, DengiAll could ease the burden on healthcare systems and complement vector control efforts, significantly altering India’s dengue response strategy."

Health Conditions A-Z

health

dengue vaccine

dengiall

indigenous dengue vaccine

india vaccine

phase 3 trials

dengue outbreak

tetravalent vaccine

Is Collagen Worsening Type 2 Diabetes?

Wildfire Smoke May Rewire Your Immune System, Scientists Warn: Here’s How It Impacts Your Health

Smartphones For Kids Becomes A Common Trend - Average Age For Smartphones Revealed To Be 9

Health News

This Is How Stress Affects Your Heart

Does Digital ‘Brain Rot’ Really Affect Your Health?

Dishes With Fermented Foods To Eat For Your Gut Health

Yoga Poses That Stimulate Good Bowel Health

Weekend Warrior Exercises For Full Body Movement

Weekend Meal Prep Ideas That Will Last You A Weekend

Easy Homemade Healthy Dishes For Long Afternoons

Silent Walking: Mental Health Booster That Keeps You Fit

Dumbbell Exercises You Can Do At Home

These Foods Are Keeping You Awake At Night

Ways to Manage Sugar Cravings

Your Body Doesn’t Want You To Lose Weight – Here's It Resists

High-Protein No Cook Dishes You Should Try

Yoga Poses That Aid In Digestion

Low Calorie Dinner Options For Weight Loss

Cardiac Arrest Vs. Heart Attack: Difference Explained Under 60 Seconds

High Protein Low-Carb Snacks To Have On The Go

Knee Exercises Desk Workers Should Do For Joint Health

Why Do I Feel Sleepy During The Day?

High Protein Early Morning Meals To Keep You Full Till Lunch

International Yoga Day 2025: Benefits of Doing Tadasana Every Morning

High-Carb Foods That Are Really Healthy

Dementia Vs Alzheimer’s: Difference Explained Under 60 Seconds

Healthy Staple Foods To Make Eating Healthy Easier

Are You Dealing With Abandonment Issues? Signs And Risk Factors

Mid-Work Healthy Snacks You Can Eat Throughout The Day

Common Mistakes You May Be Making In The Gym

Strengthen Your Legs Muscles With These Exercises

Beat Anxiety With Books: How Reading Helps With Stress

Ghee For Health: Ayurvedic Health Benefits Of Clarified Butter

Common Mistakes You Are Making While Walking

Exercises You Should Do At Home When You Skip Gym

Common Mistakes You May Be Making While Working Out

Ways You Are Runing Your Weight Loss Journey

Beyond Fruits – How To Retain Hydration And Stay Safe In Summers

Can This Extremely Hot Weather Trigger Our Mental Health?

You Are Hurting Your Gut Health With These Habits

Avoid The Heat With These Indoor Exercises

Stay Sharp! Activities That Keep Cognitive Diseases At Bay

Protect Your Cardiovascular Health With These Heart Healthy Foods

Dengue fever has been a public health crisis for decades, especially in tropical and subtropical regions, and India has been one of the worst-hit countries in recent years. With rising cases and fatal outbreaks, the country has required a reliable and inexpensive vaccine to prevent the spread of the disease. That changed with the launch of DengiAll, India's indigenous tetravalent dengue vaccine. After all these years of research, trials, and international collaboration, the vaccine is now in the last stage of testing, and a breakthrough seems at hand.Developed by the Indian Council of Medical Research (ICMR) in collaboration with Panacea Biotech, DengiAll will be a game-changer for India's battle against dengue. The vaccine is currently in Phase 3 clinical trials, which are being conducted at 19 sites in 18 states and union territories with more than 10,335 healthy volunteers enrolled so far. The trials have shown promising results, with earlier phases (1 and 2) being successful for the vaccine to combat dengue across various strains.The significance of the vaccine is not just its possibility in dengue prevention but also that it's an indigenous development, carefully crafted to fulfill India's needs. Balram Bhargava, former Director General of ICMR, who has played a key role in India's fight against COVID-19, ensured that India's first indigenous tetravalent dengue vaccine will be in the market by mid-2026—a landmark moment for India's health sector.Dengue fever, transmitted by the Aedes aegypti mosquito, is one of the most common vector-borne diseases in India, especially prevalent during the monsoon season between May and September. The disease is characterized by fever, severe headache, joint pains, and sudden drop in platelet levels. It can, in severe cases, progress to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS), which will prove fatal without urgent medical treatment. The World Health Organization (WHO) indicates that the worldwide incidence of dengue has grown eight times greater than two decades ago, thus emerging as a public health issue of major concern.DengiAll is a tetravalent vaccine, and it has the goal of protecting against all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4). This is a significant feature since dengue is a multi-serotype disease, and immunity to one serotype will not protect against others. In protecting against all four serotypes, the vaccine provides broad protection, which is extremely important in a country like India, where outbreaks are ever-present and in large part unpredictable.The vaccine development is based on the TV003/TV005 strain, which was originally developed by the United States' National Institutes of Health (NIH). The strain was licensed to Panacea Biotech, a top Indian pharma company, and was adapted for domestic use. The company has achieved significant milestones in re-developing the vaccine to meet the specific needs of the Indian population, for whom it holds a process patent for development.Highest Number of Cases Recorded In IndiaApproximately 188,401 cases were identified in 2017, with 325 deaths. Highest number of infections was reported from Tamil Nadu, followed by Kerala, Karnataka, then Punjab and West Bengal. In the 20th century, there was the significant rise in number of infections reported in 2003, 2010, 2012, and 2013, with an exponential increase beginning in 2015 onwards. During this time, repeated dengue outbreaks were reported in states of Andhra Pradesh, Goa, Delhi, Haryana, Karnataka, Gujarat, Kerala, Tamil Nadu, Punjab, and West Bengal. In 2017, dengue cases were to be the highest in India. India, in particular, has experienced frequent outbreaks in West Bengal, Uttar Pradesh, Rajasthan, Bihar, Delhi, Kerala, and Tamil Nadu. The outbreaks have claimed thousands of lives and loaded the healthcare system with a great burden. Over 5 million cases of dengue have been reported to date as of 2023, with the Indian contribution playing a significant role in the surge. Since DengiAll is presently in its final stages of trials, the vaccine is set to reduce significantly the incidence of dengue and its complications in the country.Why Dengue Cases Are On A Steady Rise?Although India has been battling with dengue for years now, the illness has also been on the rise globally. The WHO states that the number of dengue cases reported globally has grown over twice in the past few years, with a total of 10.6 million cases having been reported thus far in the year 2024 alone. The growth is driven by various factors:Warm, humid temperatures offer ideal breeding grounds for mosquitoes.Overcrowded cities with poor waste management infrastructure facilitate the disease transmission.Increased international travel has led to dengue's expansion into non-endemic areas.There is no cure for dengue known at the moment. It is treated with supportive care—hydration, management of fever, and close attention to platelet levels. If it is severe, hospitalization is required, and there are concerns regarding the burden this causes to the health system, especially in low-resource settings.The presence of a dengue vaccine like DengiAll would be a welcome preventive. While a vaccine would not replace effective measures for mosquito control, it could be an extra tool in the public health arsenal, significantly reducing the number of severe cases and fatalities.When Will Dengue Vaccine Hit the Market?So far, DengiAll is in Phase 3 trials, and although it shows a great deal of promise, it should be kept in mind that the final approval phase could take time. If the ongoing trials continue to progress well, it is hoped that the vaccine would become available by mid-2026. This is a rough estimate, though, as it includes successful completion of the clinical trials and regulatory approvals.Signs and Symptoms of Dengue FeverSymptoms of dengue fever typically appear 4 to 10 days from the time of a bite from an infected mosquito and persist for 3 to 7 days. Asymptomatic cases are most common, but about 1 in 20 individuals will experience severe dengue when the initial symptoms start to resolve. Typical symptoms of dengue fever are:High feverRashSevere pain behind the eyesNausea and vomitingMuscle, bone, and joint painIf you notice any of these symptoms, it is imperative that you receive medical care immediately, particularly if the symptoms are increasing.How Does Vaccine Affects Dengue Treatment?The DengiAll vaccine, India’s pioneering tetravalent dengue vaccine developed by Panacea Biotec, targets all four dengue serotypes, offering a preventive approach that could revolutionize dengue management. Dr. Divya Gopal, Consultant - Internal Medicine, Sir HN Reliance Foundation Hospital, Mumbai says, "Currently in Phase 3 trials with over 10,000 participants, it may reach markets by mid-2026 if successful. Unlike existing treatments, which focus on symptom management due to the absence of specific antivirals, DengiAll aims to reduce infection rates and disease severity, potentially lowering hospitalization and mortality, particularly during monsoon seasons. By shifting focus to prevention, DengiAll could ease the burden on healthcare systems and complement vector control efforts, significantly altering India’s dengue response strategy."

dengiall: india’s first indigenous dengue vaccine nears completion, set to hit markets by next year

A Loss Of Grip Strength Might Be An Early Sign Of Psychosis, Study Finds

Not From The Brain, Scientists Trace Parkinson’s Disease To This Organ In Your Body

not from the brain, scientists trace parkinson’s disease to this organ in your body

Health & Wellness

At 15, This Girl Began Walking Like A 90-Year-Old Due To A Spine Condition That Affects 1 In 10 Kids

at 15, this girl began walking like a 90-year-old due to a spine condition that affects 1 in 10 kids

Physical Manifestation Of Mental Health Problems - How Your Body Tries To Tell You It Needs Help

physical manifestation of mental health problems - how your body tries to tell you it needs help

Health And Space: How Do Astronauts Ensure Their Well-being On Space Mission?

health and space: how do astronauts ensure their well-being on space mission?

Researchers have discovered that something as simple as weakened grip strength may be an early warning sign of psychosis—a complex mental condition marked by distorted thinking, delusions, and hallucinations. Published in the American Journal of Psychiatry, the study adds to a growing body of evidence that subtle changes in physical functioning, especially motor skills, may be deeply intertwined with brain health and psychiatric conditions.

The findings point to a potential paradigm shift in how clinicians may one day screen for psychosis—by using an everyday, easily measurable physical marker. As <span>mental health</span> professionals and researchers seek better ways to identify and treat psychosis before it fully develops, the humble handgrip test may soon become a vital tool in the psychiatric toolkit.

Psychosis is a term that describes a range of symptoms where a person loses touch with reality. Classic signs include delusions (false beliefs) and hallucinations (seeing or hearing things that aren’t there). However, the journey into psychosis often begins long before these dramatic symptoms appear. Early warning signs can be subtle—changes in behavior, social withdrawal, trouble thinking clearly, or a decline in self-care.

Psychosis typically emerges in late adolescence or early adulthood, but it can affect people at any age. It’s a feature of several mental health disorders, including schizophrenia, bipolar disorder, and severe depression, and can also arise in older adults as a result of neurological conditions like Parkinson’s or Alzheimer’s disease.

The study involved 89 participants recently diagnosed with psychosis (within the past five years), compared with 51 individuals in good mental and physical health. Participants underwent grip strength tests, well-being assessments, and brain imaging scans.

Not only did those with psychosis show significantly lower grip strength, but this weakness was also tied to changes in the brain's default mode network—a complex system that becomes active during rest, daydreaming, or inward-focused thoughts. Researchers found that lower grip strength correlated with reduced connectivity in three key brain regions:

<ul><li>The anterior cingulate cortex,</li><li>The sensorimotor cortex, and</li><li>The cerebellum.</li></ul>

All three play vital roles in motor function, cognition, and emotion. When connectivity among these regions decreased, so did physical grip strength and overall psychological well-being.

<h2>Why A Strong Grip Strength Important?</h2>

Grip strength has long been recognized as a general indicator of health. Lower grip strength is associated with higher mortality risk, reduced quality of life, and poorer day-to-day functioning. But its connection to mental health—and specifically to psychosis—is a new and important insight.

“Grip strength seems to capture that things are not going well, but it hasn’t been well studied in relation to brain function or early psychosis,” said Dr. Alexandra Moussa-Tooks, senior researcher and assistant professor of psychological and brain sciences at Indiana University.

The study’s findings suggest that changes in grip strength may reflect underlying disturbances in brain network function—what researchers call “resting-state functional connectivity.” In other words, the physical symptom of a weakening grip could be a visible sign of invisible changes happening in the brain.

While it may seem far-fetched to connect your ability to open a pickle jar with your mental stability, grip strength is increasingly being recognized as a proxy for overall health—both physical and cognitive. Past research has linked low grip strength to a higher risk of cardiovascular disease, frailty, depression, and even early mortality.

This new study takes it a step further by linking grip strength to resting-state functional connectivity in the brain—a measure of how different parts of the brain interact when a person is not actively doing a task. The less synchronized these connections, the more likely a person is to experience disturbances in thought, behavior, and even basic physical abilities.

Dr. Heather Burrell Ward, lead author and assistant professor of psychiatry at Vanderbilt University Medical Center, said the findings "identify potential brain targets for new treatments for psychosis," including the possibility of using magnetic brain stimulation or exercise to strengthen neural connections.

“If Psychosis Is a Fire, Symptoms Are the Smoke”

Traditionally, treatment for psychosis has focused on managing the “smoke”—the overt symptoms like delusions and hallucinations. But as Dr. Moussa-Tooks explains, “If psychosis is a house on fire, symptoms such as delusions and hallucinations are the smoke. In a fire you don’t target the smoke, you target the fire and its source. And yet, currently that’s not how we approach treatment for psychosis.”

Motor disturbances, such as reduced grip strength, may be among the earliest signs that something is amiss in the brain. Because these changes are more fundamental and easier to measure than complex cognitive symptoms, they could help clinicians identify and address psychosis at its source—potentially before full-blown symptoms develop.

Psychosis is a complex condition with no single cause. It arises from a combination of genetic vulnerability, brain development differences, and environmental stressors or trauma. While it can be a symptom of mental illnesses like schizophrenia or bipolar disorder, it can also occur independently or as part of physical illnesses, particularly in older adults.

Recognizing early warning signs—whether behavioral, emotional, or physical—can make a crucial difference in outcomes. Early intervention is associated with better long-term recovery and improved quality of life.

Could a handgrip test become a new <span>mental health screening</span> tool? The researchers believe it's possible.

“Grip strength and other motor functions are easily assessed and more readily interpretable than complex tasks often used to study psychosis,” said Moussa-Tooks. “Our work shows that these simple metrics could have profound implications in early detection and treatment.”

Such early detection tools are especially critical, as earlier intervention in psychosis typically leads to better outcomes. The current model, which relies heavily on self-reported symptoms or behavioral changes, is reactive and often too late.

As science continues to uncover the deep connections between brain and body, one thing becomes increasingly clear—sometimes, holding on tightly might be the very first step to staying mentally well.

mental health

psychosis early signs

grip strength test

brain connectivity

mental health screening

early psychosis detection

motor function and psychosis

default mode network

Researchers have discovered that something as simple as weakened grip strength may be an early warning sign of psychosis—a complex mental condition marked by distorted thinking, delusions, and hallucinations. Published in the American Journal of Psychiatry, the study adds to a growing body of evidence that subtle changes in physical functioning, especially motor skills, may be deeply intertwined with brain health and psychiatric conditions.The findings point to a potential paradigm shift in how clinicians may one day screen for psychosis—by using an everyday, easily measurable physical marker. As mental health professionals and researchers seek better ways to identify and treat psychosis before it fully develops, the humble handgrip test may soon become a vital tool in the psychiatric toolkit.What is Psychosis?Psychosis is a term that describes a range of symptoms where a person loses touch with reality. Classic signs include delusions (false beliefs) and hallucinations (seeing or hearing things that aren’t there). However, the journey into psychosis often begins long before these dramatic symptoms appear. Early warning signs can be subtle—changes in behavior, social withdrawal, trouble thinking clearly, or a decline in self-care.Psychosis typically emerges in late adolescence or early adulthood, but it can affect people at any age. It’s a feature of several mental health disorders, including schizophrenia, bipolar disorder, and severe depression, and can also arise in older adults as a result of neurological conditions like Parkinson’s or Alzheimer’s disease.The study involved 89 participants recently diagnosed with psychosis (within the past five years), compared with 51 individuals in good mental and physical health. Participants underwent grip strength tests, well-being assessments, and brain imaging scans.Not only did those with psychosis show significantly lower grip strength, but this weakness was also tied to changes in the brain's default mode network—a complex system that becomes active during rest, daydreaming, or inward-focused thoughts. Researchers found that lower grip strength correlated with reduced connectivity in three key brain regions:The anterior cingulate cortex,The sensorimotor cortex, andThe cerebellum.All three play vital roles in motor function, cognition, and emotion. When connectivity among these regions decreased, so did physical grip strength and overall psychological well-being.Why A Strong Grip Strength Important?Grip strength has long been recognized as a general indicator of health. Lower grip strength is associated with higher mortality risk, reduced quality of life, and poorer day-to-day functioning. But its connection to mental health—and specifically to psychosis—is a new and important insight.“Grip strength seems to capture that things are not going well, but it hasn’t been well studied in relation to brain function or early psychosis,” said Dr. Alexandra Moussa-Tooks, senior researcher and assistant professor of psychological and brain sciences at Indiana University.The study’s findings suggest that changes in grip strength may reflect underlying disturbances in brain network function—what researchers call “resting-state functional connectivity.” In other words, the physical symptom of a weakening grip could be a visible sign of invisible changes happening in the brain.While it may seem far-fetched to connect your ability to open a pickle jar with your mental stability, grip strength is increasingly being recognized as a proxy for overall health—both physical and cognitive. Past research has linked low grip strength to a higher risk of cardiovascular disease, frailty, depression, and even early mortality.This new study takes it a step further by linking grip strength to resting-state functional connectivity in the brain—a measure of how different parts of the brain interact when a person is not actively doing a task. The less synchronized these connections, the more likely a person is to experience disturbances in thought, behavior, and even basic physical abilities.Dr. Heather Burrell Ward, lead author and assistant professor of psychiatry at Vanderbilt University Medical Center, said the findings "identify potential brain targets for new treatments for psychosis," including the possibility of using magnetic brain stimulation or exercise to strengthen neural connections.Symptoms of Psychosis“If Psychosis Is a Fire, Symptoms Are the Smoke”Traditionally, treatment for psychosis has focused on managing the “smoke”—the overt symptoms like delusions and hallucinations. But as Dr. Moussa-Tooks explains, “If psychosis is a house on fire, symptoms such as delusions and hallucinations are the smoke. In a fire you don’t target the smoke, you target the fire and its source. And yet, currently that’s not how we approach treatment for psychosis.”Motor disturbances, such as reduced grip strength, may be among the earliest signs that something is amiss in the brain. Because these changes are more fundamental and easier to measure than complex cognitive symptoms, they could help clinicians identify and address psychosis at its source—potentially before full-blown symptoms develop.What Causes Psychosis?Psychosis is a complex condition with no single cause. It arises from a combination of genetic vulnerability, brain development differences, and environmental stressors or trauma. While it can be a symptom of mental illnesses like schizophrenia or bipolar disorder, it can also occur independently or as part of physical illnesses, particularly in older adults.Recognizing early warning signs—whether behavioral, emotional, or physical—can make a crucial difference in outcomes. Early intervention is associated with better long-term recovery and improved quality of life.Could a handgrip test become a new mental health screening tool? The researchers believe it's possible.“Grip strength and other motor functions are easily assessed and more readily interpretable than complex tasks often used to study psychosis,” said Moussa-Tooks. “Our work shows that these simple metrics could have profound implications in early detection and treatment.”Such early detection tools are especially critical, as earlier intervention in psychosis typically leads to better outcomes. The current model, which relies heavily on self-reported symptoms or behavioral changes, is reactive and often too late.As science continues to uncover the deep connections between brain and body, one thing becomes increasingly clear—sometimes, holding on tightly might be the very first step to staying mentally well.

a loss of grip strength might be an early sign of psychosis, study finds

Simple Capsule Sponge Test Can Replace Endoscopies And Make Cancer Screening Easier

A Simple Capsule Sponge Test Can Replace Endoscopies And Make Cancer Screening Easier

Could Anti-Ageing Drugs Be Shortening Your Life Span?

could anti-ageing drugs be shortening your life span?

New Test Predicts And Helps Prevent Miscarriage Before You Are Even Pregnant

new test predicts and helps prevent miscarriage before you are even pregnant

wildfire smoke may rewire your immune system, scientists warn: here’s how it impacts your health

With rates of <span>esophageal cancer</span> having quadrupled since the 1970s and fewer than 20% of patients surviving five years post-diagnosis, early detection is more critical than ever. The <span>capsule sponge test</span> offers a powerful tool for risk stratification, ensuring that high-risk individuals continue receiving endoscopy while sparing low-risk patients from unnecessary invasive procedures.

The gold standard for monitoring patients at risk of esophageal (throat) cancer has been the endoscopy—a procedure that, while effective, is invasive, uncomfortable, and resource-intensive. Now, a simple device known as the “pill-on-a-string” or capsule sponge test is emerging as a transformative alternative, promising to make screening and surveillance for <span>throat cancer</span> faster, less invasive, and more accessible for millions worldwide.

The concept is ingeniously simple: patients swallow a small capsule attached to a string. Once in the stomach, the capsule dissolves, releasing a sponge that expands to about the size of a coin. Healthcare professionals then gently pull the sponge back up by the string, allowing it to collect cells from the lining of the esophagus as it travels upward. The entire procedure takes about ten minutes and can be performed by a nurse in a clinic or even a mobile screening van.

Barrett’s esophagus is a chronic condition in which prolonged acid reflux damages the lining of the esophagus. Over time, the damaged cells can become precancerous, forming dysplasia, and potentially progressing into esophageal adenocarcinoma—a type of throat cancer with notoriously poor survival rates. Despite the relatively low annual conversion rate from Barrett’s to cancer (approximately 0.5%), regular monitoring is essential.

Traditionally, endoscopy has been the go-to method for this surveillance. However, it is not without drawbacks: sedation, fasting, potential complications, and significant cost. This is where the pill-on-a-string method is poised to transform care—making monitoring more accessible, efficient, and patient-friendly.

<h2>What Is the Pill-on-a-String Test?</h2>

The new test involves swallowing a capsule containing a compressed sponge. Once it reaches the stomach, the capsule dissolves, allowing the sponge to expand. Attached to a string, the sponge is gently pulled back up through the esophagus, collecting cells from the lining along the way. These cells are then analyzed in a lab for red-flag changes indicative of dysplasia or early cancer.

Though the idea may initially sound uncomfortable, the experience has proven to be far more tolerable than an endoscopy. For Duncan Cook, a 57-year-old heating engineer from Cambridge, who has endured nearly two decades of endoscopic monitoring, the change was welcome.

“The first time I had the sponge, I was a bit nervous,” Cook shared in a news release. “It’s quite a big pill to swallow, but it’s much better than going for endoscopies... I was able to have the test done and go right back to work after.”

A major challenge is that symptoms often overlap with benign conditions like heartburn, leading to late diagnoses when treatment options are limited. Early detection is critical: when caught at stage 1, five-year survival rates can reach 63%. This is why regular surveillance of high-risk individuals—particularly those with Barrett’s esophagus—is so important.

In a large multi-center trial involving 910 patients across 13 hospitals in the U.K., researchers from the University of Cambridge and Queen Mary University of London evaluated the effectiveness of the capsule sponge test. Participants—all of whom were already being monitored for Barrett’s esophagus—underwent both the new test and a standard endoscopy for comparison. Findings from the study, recently published in The Lancet, are compelling:

<ul><li>54% of patients were classified as low-risk after the sponge test, showing no cellular changes that could indicate progression to cancer.</li><li>Only 0.4% of the low-risk group were later found via endoscopy to have high-risk cell changes.</li><li>No cancers were detected in those flagged as low-risk by the sponge test.</li></ul>

These results suggest that more than half of the patients undergoing routine endoscopies could safely switch to the capsule test without compromising diagnostic accuracy.

“Our findings suggest that the capsule sponge could help stratify patients with Barrett’s esophagus by risk,” said Dr. Peter Sasieni, director of the Cancer Research UK Cancer Prevention Trials Unit. “Given the low risk of progression in these individuals, it should be safe to replace their usual endoscopy with the capsule sponge.”

The research team isn’t stopping here. Scientists are now working to refine the sponge test further by enhancing laboratory analysis of the collected cell samples. Artificial intelligence (AI) is being evaluated to assist in identifying early signs of dysplasia, potentially boosting accuracy and reducing human error.

Professor Rebecca Fitzgerald, director of the Early Cancer Institute at Cambridge, noted, “We need an alternative surveillance method that’s less invasive, easier to administer and more reliable… Endoscopies aren’t always a reliable way of spotting early cancers, and they depend on the skill of the person doing it."

throat cancer

pill on a string

capsule sponge test

throat cancer detection

barretts esophagus screening

non invasive cancer test

esophageal cancer

early cancer diagnosis

With rates of esophageal cancer having quadrupled since the 1970s and fewer than 20% of patients surviving five years post-diagnosis, early detection is more critical than ever. The capsule sponge test offers a powerful tool for risk stratification, ensuring that high-risk individuals continue receiving endoscopy while sparing low-risk patients from unnecessary invasive procedures.The gold standard for monitoring patients at risk of esophageal (throat) cancer has been the endoscopy—a procedure that, while effective, is invasive, uncomfortable, and resource-intensive. Now, a simple device known as the “pill-on-a-string” or capsule sponge test is emerging as a transformative alternative, promising to make screening and surveillance for throat cancer faster, less invasive, and more accessible for millions worldwide.The concept is ingeniously simple: patients swallow a small capsule attached to a string. Once in the stomach, the capsule dissolves, releasing a sponge that expands to about the size of a coin. Healthcare professionals then gently pull the sponge back up by the string, allowing it to collect cells from the lining of the esophagus as it travels upward. The entire procedure takes about ten minutes and can be performed by a nurse in a clinic or even a mobile screening van.Barrett’s esophagus is a chronic condition in which prolonged acid reflux damages the lining of the esophagus. Over time, the damaged cells can become precancerous, forming dysplasia, and potentially progressing into esophageal adenocarcinoma—a type of throat cancer with notoriously poor survival rates. Despite the relatively low annual conversion rate from Barrett’s to cancer (approximately 0.5%), regular monitoring is essential.Traditionally, endoscopy has been the go-to method for this surveillance. However, it is not without drawbacks: sedation, fasting, potential complications, and significant cost. This is where the pill-on-a-string method is poised to transform care—making monitoring more accessible, efficient, and patient-friendly.What Is the Pill-on-a-String Test?The new test involves swallowing a capsule containing a compressed sponge. Once it reaches the stomach, the capsule dissolves, allowing the sponge to expand. Attached to a string, the sponge is gently pulled back up through the esophagus, collecting cells from the lining along the way. These cells are then analyzed in a lab for red-flag changes indicative of dysplasia or early cancer.Though the idea may initially sound uncomfortable, the experience has proven to be far more tolerable than an endoscopy. For Duncan Cook, a 57-year-old heating engineer from Cambridge, who has endured nearly two decades of endoscopic monitoring, the change was welcome.“The first time I had the sponge, I was a bit nervous,” Cook shared in a news release. “It’s quite a big pill to swallow, but it’s much better than going for endoscopies... I was able to have the test done and go right back to work after.”A major challenge is that symptoms often overlap with benign conditions like heartburn, leading to late diagnoses when treatment options are limited. Early detection is critical: when caught at stage 1, five-year survival rates can reach 63%. This is why regular surveillance of high-risk individuals—particularly those with Barrett’s esophagus—is so important.In a large multi-center trial involving 910 patients across 13 hospitals in the U.K., researchers from the University of Cambridge and Queen Mary University of London evaluated the effectiveness of the capsule sponge test. Participants—all of whom were already being monitored for Barrett’s esophagus—underwent both the new test and a standard endoscopy for comparison. Findings from the study, recently published in The Lancet, are compelling:54% of patients were classified as low-risk after the sponge test, showing no cellular changes that could indicate progression to cancer.Only 0.4% of the low-risk group were later found via endoscopy to have high-risk cell changes.No cancers were detected in those flagged as low-risk by the sponge test.These results suggest that more than half of the patients undergoing routine endoscopies could safely switch to the capsule test without compromising diagnostic accuracy.“Our findings suggest that the capsule sponge could help stratify patients with Barrett’s esophagus by risk,” said Dr. Peter Sasieni, director of the Cancer Research UK Cancer Prevention Trials Unit. “Given the low risk of progression in these individuals, it should be safe to replace their usual endoscopy with the capsule sponge.”The research team isn’t stopping here. Scientists are now working to refine the sponge test further by enhancing laboratory analysis of the collected cell samples. Artificial intelligence (AI) is being evaluated to assist in identifying early signs of dysplasia, potentially boosting accuracy and reducing human error.Professor Rebecca Fitzgerald, director of the Early Cancer Institute at Cambridge, noted, “We need an alternative surveillance method that’s less invasive, easier to administer and more reliable… Endoscopies aren’t always a reliable way of spotting early cancers, and they depend on the skill of the person doing it."

a simple capsule sponge test can replace endoscopies and make cancer screening easier

Ishita Roy

Coles Recalls Peanut Butter Products After Cancer-causing Toxins Were Found

Nutrition

With Fourth Of July Around The Corner, Are You Making These Food Safety Mistakes At Your Cookout?

with fourth of july around the corner, are you making these food safety mistakes at your cookout?

Hepatitis B Nears Elimination In Uzbek Children After Years Of Immunization

hepatitis b nears elimination in uzbek children after years of immunization

Food Standards Australia New Zealand is urging people to not consume two <span>peanut butter</span> products by Coles. These two varieties are Coles Smooth peanut butter and Coles Crunchy peanut butter, which have been found to contain mycotoxin and aflatoxin. Coles has also recalled these two products. The question is raised for products with the batch marked best before February 5, 2027. 

Coles' recalling means that people can return these products for a full refund. 

The toxins found in these products are said to increase the risk of liver cancer. An alert has been issued, which reads: “Coles Online customers can receive a refund or credit by contacting Coles Online Customer Care on 1800 455 400. Any consumers concerned about their health should seek medical advice.”

Also Read: <a href="https://www.healthandme.com/health-news/hepatitis-b-nears-elimination-in-uzbek-children-after-years-of-immunization-article-152189117" data-type="tilCustomLink" target="_blank">Hepatitis B Nears Elimination In Uzbek Children After Years Of Immunization</a>

<h2>What Are These Toxins, How Does It Impact Our Health?</h2>

As per the World Health Organization (WHO), mycotoxins are toxic substances produced naturally by certain types of mould (fungi). These moulds can grow on a wide variety of foods—such as grains, dried fruits, nuts, and spices—especially in warm, damp, and humid environments. The contamination can occur either before harvest or after, during storage or even on the food itself. Alarmingly, most mycotoxins are highly stable and can survive food processing methods.

There are hundreds of known mycotoxins, but a few pose significant health risks to both humans and animals. These include aflatoxins, ochratoxin A, patulin, fumonisins, zearalenone, and nivalenol/deoxynivalenol. Mycotoxins enter the food chain when crops are infected with mould. People can be exposed either by consuming contaminated food directly or indirectly—most commonly through animal products like milk, when livestock are fed mould-contaminated feed.

Mycotoxins can contaminate food before harvest (in the field) or afterward during storage and processing. Since most mycotoxins are chemically stable, they can survive food manufacturing and cooking processes, making them hard to eliminate completely.

Mycotoxins can pose serious health risks to both humans and animals. Their effects can range from sudden poisoning to long-term health issues such as:

<ul><li>Suppressed immune response</li><li>Liver damage</li><li>Increased cancer risk</li></ul>

Livestock can also be exposed through contaminated feed, and humans may indirectly consume these toxins through animal products like milk.

Also Read: <a href="https://www.healthandme.com/health-news/national-doctors-day-july-1-2025-theme-who-heals-the-healer-know-more-about-its-history-and-significance--article-152188972" data-type="tilCustomLink" target="_blank">'Who Heals The Healer?' What Makes The National Doctors' Day 2025 Theme So Relevant?</a>

Though hundreds of mycotoxins have been identified, a few are especially harmful and frequently found in food:

<ul><li>Aflatoxins (among the most toxic, produced by Aspergillus moulds found in soil and stored grains)</li><li>Ochratoxin A</li><li>Patulin</li><li>Fumonisins</li><li>Zearalenone</li><li>Nivalenol/Deoxynivalenol (DON)</li></ul>

As per the National Cancer Institute, US, aflatoxins are a group of toxic compounds produced by specific types of fungi, primarily Aspergillus flavus and Aspergillus parasiticus. These fungi thrive in warm, humid climates and commonly infect crops like maize (corn), peanuts, cottonseed, and various tree nuts. Contamination can occur at multiple stages—while the crops are growing in the field, during harvest, or later in storage.

The National Cancer Institute also notes that exposure to aflatoxins is associated with an increased risk of liver cancer. 

Another 2013 study published in World Journal of Gastroenterology notes that while Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide, it is caused by aflatoxin. The study notes that aflatoxin is a food contaminant produced by the fungi Aspergillus flavus and Aspergillus parasiticus, is a known human carcinogen that has been shown to be a causative agent in the pathogenesis of HCC. In fact, Aflatoxin B1 has been classified by the WHO as a “group A” carcinogen because of it’s proven contribution to the pathogenesis of HCC.

peanut butter recall

coles recall peanut butter

health news

health news australia

australia health news

peanut butter coles recall

Peanut Butter

Food Standards Australia New Zealand is urging people to not consume two peanut butter products by Coles. These two varieties are Coles Smooth peanut butter and Coles Crunchy peanut butter, which have been found to contain mycotoxin and aflatoxin. Coles has also recalled these two products. The question is raised for products with the batch marked best before February 5, 2027. Coles' recalling means that people can return these products for a full refund. The toxins found in these products are said to increase the risk of liver cancer. An alert has been issued, which reads: “Coles Online customers can receive a refund or credit by contacting Coles Online Customer Care on 1800 455 400. Any consumers concerned about their health should seek medical advice.”Also Read: Hepatitis B Nears Elimination In Uzbek Children After Years Of ImmunizationWhat Are These Toxins, How Does It Impact Our Health?Mycotoxins As per the World Health Organization (WHO), mycotoxins are toxic substances produced naturally by certain types of mould (fungi). These moulds can grow on a wide variety of foods—such as grains, dried fruits, nuts, and spices—especially in warm, damp, and humid environments. The contamination can occur either before harvest or after, during storage or even on the food itself. Alarmingly, most mycotoxins are highly stable and can survive food processing methods.There are hundreds of known mycotoxins, but a few pose significant health risks to both humans and animals. These include aflatoxins, ochratoxin A, patulin, fumonisins, zearalenone, and nivalenol/deoxynivalenol. Mycotoxins enter the food chain when crops are infected with mould. People can be exposed either by consuming contaminated food directly or indirectly—most commonly through animal products like milk, when livestock are fed mould-contaminated feed.Where Are They Found?Mycotoxins can contaminate food before harvest (in the field) or afterward during storage and processing. Since most mycotoxins are chemically stable, they can survive food manufacturing and cooking processes, making them hard to eliminate completely.Mycotoxins can pose serious health risks to both humans and animals. Their effects can range from sudden poisoning to long-term health issues such as:Suppressed immune responseLiver damageIncreased cancer riskLivestock can also be exposed through contaminated feed, and humans may indirectly consume these toxins through animal products like milk.Also Read: 'Who Heals The Healer?' What Makes The National Doctors' Day 2025 Theme So Relevant?Common Mycotoxins to Watch ForThough hundreds of mycotoxins have been identified, a few are especially harmful and frequently found in food:Aflatoxins (among the most toxic, produced by Aspergillus moulds found in soil and stored grains)Ochratoxin APatulinFumonisinsZearalenoneNivalenol/Deoxynivalenol (DON)What Are Aflatoxins?As per the National Cancer Institute, US, aflatoxins are a group of toxic compounds produced by specific types of fungi, primarily Aspergillus flavus and Aspergillus parasiticus. These fungi thrive in warm, humid climates and commonly infect crops like maize (corn), peanuts, cottonseed, and various tree nuts. Contamination can occur at multiple stages—while the crops are growing in the field, during harvest, or later in storage.The National Cancer Institute also notes that exposure to aflatoxins is associated with an increased risk of liver cancer. Another 2013 study published in World Journal of Gastroenterology notes that while Hepatocellular carcinoma (HCC) is one of the leading causes of cancer deaths worldwide, it is caused by aflatoxin. The study notes that aflatoxin is a food contaminant produced by the fungi Aspergillus flavus and Aspergillus parasiticus, is a known human carcinogen that has been shown to be a causative agent in the pathogenesis of HCC. In fact, Aflatoxin B1 has been classified by the WHO as a “group A” carcinogen because of it’s proven contribution to the pathogenesis of HCC.

coles recalls peanut butter products after cancer-causing toxins were found

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.